Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/5/2025

Hypertension Management Guidelines

Introduction to Hypertension Treatment

  • The American Heart Association recommends the first-line treatment for hypertension to include lifestyle modifications and pharmacological therapy with one of four medication classes: thiazide or thiazide-like diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or calcium channel blockers (CCBs) 1

Lifestyle Modifications

  • Lifestyle modifications should be implemented for all patients with blood pressure >120/80 mmHg, including weight loss or maintenance of healthy body weight for overweight or obese individuals, although the original source of this information is not preferred, it is also stated in other sources 1
  • The American College of Cardiology recommends a DASH (Dietary Approaches to Stop Hypertension) eating pattern with reduced sodium (<2,300 mg/day) and increased potassium intake, as stated in Trends in Cardiovascular Medicine 1
  • Regular physical activity (at least 150 minutes of moderate-intensity aerobic activity per week) is recommended for patients with hypertension 1

Pharmacological Therapy

  • The first-line medication classes for hypertension treatment are thiazide or thiazide-like diuretics, ACE inhibitors, ARBs, and dihydropyridine calcium channel blockers, as recommended by the American Heart Association 1
  • For patients with BP between 130/80 mmHg and 150/90 mmHg, the initial treatment strategy is to start with a single drug, according to the Hypertension journal 4
  • For patients with BP ≥150/90 mmHg, the initial treatment strategy is to start with two antihypertensive medications, as stated in the Hypertension journal 4

Special Population Considerations

  • For black patients, calcium channel blockers or thiazide diuretics are recommended as first-line monotherapy, according to the Hypertension journal 3
  • When combination therapy is needed for black patients, a CCB plus a thiazide-like diuretic or CCB plus an ARB is recommended, as stated in the Hypertension journal 3
  • For patients with albuminuria or coronary artery disease, an ACE inhibitor or ARB is recommended as first-line therapy, although the original source of this information is not preferred, it is also stated in other sources 1

Treatment Algorithm

  • For stage 1 hypertension (BP 130-159/80-99 mmHg), lifestyle modifications should be started for all patients, and drug therapy should be initiated immediately for high-risk patients, as recommended by the Hypertension journal 4
  • For non-black patients, a low-dose ACE inhibitor or ARB should be started, and increased to full dose if needed, according to the Hypertension journal 4
  • For black patients, a low-dose ARB plus CCB or CCB plus thiazide/thiazide-like diuretic should be started, and increased to full dose if needed, as stated in the Hypertension journal 4

Important Considerations

  • The target BP should generally be <130/80 mmHg for most adults, with individualization for elderly patients based on frailty, as recommended by the Hypertension journal 4
  • Serum creatinine and potassium levels should be monitored when using ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists, according to the Hypertension journal 4
  • Single-pill combinations may improve medication adherence, as stated in the Trends in Cardiovascular Medicine journal 1
  • Combining ACE inhibitors with ARBs should be avoided due to increased risk of adverse effects without additional benefit, according to the Hypertension journal 4

Monitoring

  • Follow-up is recommended 7-14 days after initiation or dose changes of medications, as stated in the Hypertension journal 4
  • The goal is to achieve BP target within 3 months, according to the Hypertension journal 4
  • Regular monitoring of kidney function and electrolytes is essential with many antihypertensive medications, as recommended by the Hypertension journal 4